Fig. 3: SOF10 shows antifibrotic activity in liver fibrosis model.
From: Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety
Liver antifibrotic activity was evaluated in both short term and long term CDAHFD-fed mice. a Mice fed a CDAHFD for 3 weeks to induce NASH/liver fibrosis were subcutaneously injected with either isotype control or SOF10 (mFc) once per week. b Antifibrotic activity was evaluated by measuring Serpine1, Col1a1, and Col3a1 mRNA in the liver. RNA was extracted from the liver at necropsy and gene expression was analyzed by quantitative RT–PCR. N = 3 in the normal diet group and N = 9 in each the disease control and SOF10 treatment groups. c Mice fed a CDAHFD for 9 weeks to induce NASH/liver fibrosis were subcutaneously injected with either isotype control or SOF10 once per week. d Antifibrotic activity was evaluated by measuring Serpine1, Col1a1, and Col3a1 mRNA in the liver. RNA was extracted from the liver at necropsy and gene expression was analyzed by quantitative RT–PCR. e Liver fibrosis was evaluated by measuring hydroxyproline levels. N = 5 in the normal diet group and N = 15 in each the disease control and SOF10 treatment groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns: P > 0.05; unpaired two-tailed Student’s t test. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001; ns: P > 0.05; Dunnett’s multiple comparisons test. The data are presented as the means ± SEMs.
